IS8843A - Hálfmálmaprótínasa hindra mót - Google Patents

Hálfmálmaprótínasa hindra mót

Info

Publication number
IS8843A
IS8843A IS8843A IS8843A IS8843A IS 8843 A IS8843 A IS 8843A IS 8843 A IS8843 A IS 8843A IS 8843 A IS8843 A IS 8843A IS 8843 A IS8843 A IS 8843A
Authority
IS
Iceland
Prior art keywords
alkyl
alkylaryl
cor
optionally substituted
bond
Prior art date
Application number
IS8843A
Other languages
English (en)
Inventor
Simon Gaines
Ian Peter Holmes
Stephen Lewis Martin
Stephen Paul Watson
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of IS8843A publication Critical patent/IS8843A/is

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035Isoindoles, e.g. phthalimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • C07D239/54Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Soft Magnetic Materials (AREA)
  • Indole Compounds (AREA)
  • Anti-Oxidant Or Stabilizer Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Lubricants (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IS8843A 2003-09-13 2009-08-19 Hálfmálmaprótínasa hindra mót IS8843A (is)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0321538.1A GB0321538D0 (en) 2003-09-13 2003-09-13 Therapeutically useful compounds

Publications (1)

Publication Number Publication Date
IS8843A true IS8843A (is) 2009-08-19

Family

ID=29227079

Family Applications (2)

Application Number Title Priority Date Filing Date
IS8268A IS2622B (is) 2003-09-13 2006-01-26 Hálfmálmprótínasa hindra mót
IS8843A IS8843A (is) 2003-09-13 2009-08-19 Hálfmálmaprótínasa hindra mót

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IS8268A IS2622B (is) 2003-09-13 2006-01-26 Hálfmálmprótínasa hindra mót

Country Status (28)

Country Link
US (3) US7601729B2 (is)
EP (3) EP1663970B1 (is)
JP (3) JP2007505081A (is)
KR (3) KR20060120648A (is)
CN (1) CN1849306B (is)
AT (2) ATE502922T1 (is)
AU (1) AU2004272280C1 (is)
BR (1) BRPI0413791A (is)
CA (1) CA2538315C (is)
CY (1) CY1109400T1 (is)
DE (2) DE602004017622D1 (is)
DK (1) DK1663970T3 (is)
ES (2) ES2314436T3 (is)
GB (1) GB0321538D0 (is)
HR (1) HRP20080668T3 (is)
IL (1) IL173305A (is)
IS (2) IS2622B (is)
MA (1) MA28039A1 (is)
MX (1) MXPA06002458A (is)
NO (1) NO20060540L (is)
NZ (2) NZ545211A (is)
PL (1) PL1663970T3 (is)
PT (1) PT1663970E (is)
RU (2) RU2370488C2 (is)
SG (1) SG145685A1 (is)
SI (1) SI1663970T1 (is)
WO (1) WO2005026120A1 (is)
ZA (1) ZA200602070B (is)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0321538D0 (en) * 2003-09-13 2003-10-15 Glaxo Group Ltd Therapeutically useful compounds
NZ560803A (en) * 2005-02-22 2010-10-29 Ranbaxy Lab Ltd 5-phenyl-pentanoic acid derivatives as matrix metalloproteinase inhibitors for the treatment of asthma and other diseases
NZ574905A (en) * 2006-08-22 2011-12-22 Ranbaxy Lab Ltd Matrix metalloproteinase inhibitors
AU2013200728B2 (en) * 2006-08-22 2014-12-18 Sun Pharmaceutical Industries Limited Matrix metalloproteinase inhibitors
EP2520561B1 (en) 2007-06-08 2016-02-10 MannKind Corporation IRE-1A Inhibitors
FR2949463B1 (fr) * 2009-08-26 2011-09-16 Commissariat Energie Atomique Inhibiteurs de mmp
WO2012014114A1 (en) 2010-07-30 2012-02-02 Ranbaxy Laboratories Limited Matrix metalloproteinase inhibitors
SG188642A1 (en) 2010-09-24 2013-05-31 Ranbaxy Lab Ltd Matrix metalloproteinase inhibitors
US20160045463A1 (en) 2012-11-28 2016-02-18 Universidad De Salamanca Use of metalloprotease inhibitors in the treatment of polycystic liver diseases
SMT202200201T1 (it) 2016-02-12 2022-07-21 Cytokinetics Inc Derivati di tetraidroisochinolina
JP7143334B2 (ja) * 2017-06-13 2022-09-28 エシコン エルエルシー 治癒を制御させる手術用ステープラ

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4102024A1 (de) * 1991-01-24 1992-07-30 Thomae Gmbh Dr K Biphenylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
WO1995029901A1 (en) * 1994-04-28 1995-11-09 Uniroyal Chemical Company, Inc. Fungicidal azole derivatives
SK73998A3 (en) * 1995-12-06 1999-02-11 Astra Pharma Prod Compounds
CA2251820C (en) * 1996-04-19 2007-03-27 Akzo Nobel Nv Substituted benzylamines and their use for the treatment of depression
HRP970246B1 (en) * 1996-05-15 2002-04-30 Bayer Ag Substituted oxobutric acids as matrix metalloprotease inhibitors
US6870058B2 (en) * 1996-12-03 2005-03-22 The Trustees Of The University Of Pennsylvania Compounds which mimic the chemical and biological properties of discodermolide
US20050065353A1 (en) * 1996-12-03 2005-03-24 Smith Amos B. Synthetic techniques and intermediates for polyhydroxy dienyl lactones and mimics thereof
US5789605A (en) * 1996-12-03 1998-08-04 Trustees Of The University Of Pennsylvania Synthetic techniques and intermediates for polyhydroxy, dienyl lactones and mimics thereof
US6096904A (en) 1996-12-03 2000-08-01 The Trustees Of The University Of Pennsylvania Synthetic techniques and intermediates for polyhydroxy, dienyl lactone derivatives
US6242616B1 (en) * 1996-12-03 2001-06-05 The Trustees Of The University Of Pennsylvania Synthetic techniques and intermediates for polyhydroxy, dienyl lactone derivatives
US5804581A (en) * 1997-05-15 1998-09-08 Bayer Corporation Inhibition of matrix metalloproteases by substituted phenalkyl compounds
US6608052B2 (en) * 2000-02-16 2003-08-19 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as anti-inflammatory agents
CA2490819A1 (en) * 2001-04-13 2002-10-24 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as anti-inflammatory agents
US7102008B2 (en) * 2002-08-01 2006-09-05 Bristol-Myers Squibb Company Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme
PL378238A1 (pl) * 2002-11-19 2006-03-20 Galderma Research & Development, S.N.C. Związki biaromatyczne, które aktywują receptory typu PPAR<$Egamma>, oraz ich zastosowanie w kompozycjach kosmetycznych albo farmaceutycznych
GB0312654D0 (en) * 2003-06-03 2003-07-09 Glaxo Group Ltd Therapeutically useful compounds
GB0314488D0 (en) * 2003-06-20 2003-07-23 Glaxo Group Ltd Therapeutically useful compounds
GB0319069D0 (en) * 2003-08-14 2003-09-17 Glaxo Group Ltd Therapeutically useful compounds
GB0321538D0 (en) * 2003-09-13 2003-10-15 Glaxo Group Ltd Therapeutically useful compounds
NZ560803A (en) * 2005-02-22 2010-10-29 Ranbaxy Lab Ltd 5-phenyl-pentanoic acid derivatives as matrix metalloproteinase inhibitors for the treatment of asthma and other diseases
NZ574905A (en) * 2006-08-22 2011-12-22 Ranbaxy Lab Ltd Matrix metalloproteinase inhibitors

Also Published As

Publication number Publication date
ES2362954T3 (es) 2011-07-15
IS8268A (is) 2006-01-26
RU2006106850A (ru) 2007-10-20
JP2012107031A (ja) 2012-06-07
EP1663970B1 (en) 2008-11-05
RU2370488C2 (ru) 2009-10-20
KR20060120648A (ko) 2006-11-27
SG145685A1 (en) 2008-09-29
BRPI0413791A (pt) 2006-11-07
CN1849306B (zh) 2014-01-29
KR20120007566A (ko) 2012-01-20
IS2622B (is) 2010-05-15
RU2008146479A (ru) 2010-06-20
JP2007505081A (ja) 2007-03-08
CN1849306A (zh) 2006-10-18
EP1663970A1 (en) 2006-06-07
US20090082377A1 (en) 2009-03-26
SI1663970T1 (sl) 2009-04-30
US20100029699A1 (en) 2010-02-04
MXPA06002458A (es) 2006-06-20
EP2042488B1 (en) 2011-03-23
DK1663970T3 (da) 2009-01-12
DE602004017622D1 (de) 2008-12-18
IL173305A0 (en) 2006-06-11
US8343986B2 (en) 2013-01-01
HRP20080668T3 (hr) 2009-02-28
EP2042488A1 (en) 2009-04-01
AU2004272280B2 (en) 2011-04-21
JP2011231118A (ja) 2011-11-17
DE602004031991D1 (de) 2011-05-05
CA2538315C (en) 2014-04-08
NO20060540L (no) 2006-04-04
AU2004272280A1 (en) 2005-03-24
GB0321538D0 (en) 2003-10-15
KR20130079628A (ko) 2013-07-10
US7601729B2 (en) 2009-10-13
HK1092141A1 (en) 2007-02-02
CA2538315A1 (en) 2005-03-24
PT1663970E (pt) 2009-01-09
ATE413384T1 (de) 2008-11-15
CY1109400T1 (el) 2014-07-02
US8263602B2 (en) 2012-09-11
US20060293353A1 (en) 2006-12-28
ES2314436T3 (es) 2009-03-16
IL173305A (en) 2011-01-31
PL1663970T3 (pl) 2009-04-30
MA28039A1 (fr) 2006-07-03
ATE502922T1 (de) 2011-04-15
WO2005026120A1 (en) 2005-03-24
ZA200602070B (en) 2007-05-30
EP2295408A1 (en) 2011-03-16
AU2004272280C1 (en) 2011-10-27
NZ545211A (en) 2009-01-31
NZ573479A (en) 2010-09-30

Similar Documents

Publication Publication Date Title
IS8843A (is) Hálfmálmaprótínasa hindra mót
ATE362910T1 (de) Matrix metalloprotease inhibitoren
NO904569L (no) Benzimidazolderivater og fremgangsmaate for deres fremstilling.
DE2960820D1 (en) Carbostyrile derivatives, processes for their preparation and pharmaceutical compositions containing them
DE3883140D1 (de) Imidazo(2,1-b)benzothiazole und ihre saeureadditionssalze, verfahren und zwischenprodukte zu ihrer herstellung, ihre verwendung als arzneimittel und diese enthaltende pharmazeutische zubereitungen.
EA200300044A1 (ru) Новые замещенные фталиды, способ их получения и содержащие их фармацевтические композиции
EA200100090A2 (ru) Новые пиперидин-4-сульфонамидные производные, способ их получения и содержащие их фармацевтические композиции
EA199901034A3 (ru) Новые соединения 1,2-дитиолана, способ их получения и содержащие их фармацевтические составы
ATE239021T1 (de) Metalloproteaseinhibitoren, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
GB1398687A (en) Substituted oxazolidinones and pharmaceutical uses thereof
DK1188752T3 (da) Fremgangsmåde til fremstilling af substitueret alkylaminderivat
ES2058182T3 (es) Analogos de mitomicina. un procedimiento para su preparacion y composiciones farmaceuticas.
GB1183442A (is)
PT955310E (pt) Novos derivados do acido (3,4,7,8,9,10)-hexa-hidro-6,10-dioxo-6h-piridazino[1,2-a] [1,2]diazepina-1-carboxilico, seu metodo de preaparacaoe sua aplicacao na preparacao de medicamentos
NO903084D0 (no) Farmasoeytisk anvendbare thiazol-derivater og fremgangsmaate for deres fremstilling.